{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:55:54Z","timestamp":1789433754895,"version":"build-2803163510"},"reference-count":46,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,5,21]]},"abstract":"<jats:p>\n                    Third-generation cephalosporin (3GC)-resistant\n                    <jats:italic>Enterobacteriaceae<\/jats:italic>\n                    are classified as critical priority pathogens, with extended-spectrum \u03b2-lactamases (ESBLs) as principal resistance determinants. Enmetazobactam (formerly AAI101) is a novel ESBL inhibitor developed in combination with cefepime for empirical treatment of serious Gram-negative infections in settings where ESBLs are prevalent. Cefepime-enmetazobactam has been investigated in a phase 3 trial in patients with complicated urinary tract infections or acute pyelonephritis.\n                  <\/jats:p>","DOI":"10.1128\/aac.00078-20","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T18:20:44Z","timestamp":1585851644000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":42,"title":["Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined with Cefepime in a Neutropenic Murine Thigh Infection Model"],"prefix":"10.1128","volume":"64","author":[{"given":"Fabian","family":"Bernhard","sequence":"first","affiliation":[{"name":"LYO-X GmbH, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Odedra","sequence":"additional","affiliation":[{"name":"Evotec (UK) Ltd., Cheshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Sordello","sequence":"additional","affiliation":[{"name":"Evotec (UK) Ltd., Cheshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Cardin","sequence":"additional","affiliation":[{"name":"Aptuit (Verona) Srl, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Franzoni","sequence":"additional","affiliation":[{"name":"Aptuit (Verona) Srl, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Charrier","sequence":"additional","affiliation":[{"name":"IHMA Europe S\u00e0rl, Monthey, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Belley","sequence":"additional","affiliation":[{"name":"Allecra Therapeutics SAS, Saint-Louis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Warn","sequence":"additional","affiliation":[{"name":"Evotec (UK) Ltd., Cheshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Machacek","sequence":"additional","affiliation":[{"name":"LYO-X GmbH, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0377-9446","authenticated-orcid":false,"given":"Philipp","family":"Knechtle","sequence":"additional","affiliation":[{"name":"Allecra Therapeutics SAS, Saint-Louis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30278-X"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01076-18"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy347"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.03.030"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx181"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12565"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix034"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00514-19"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-019-4648-7"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.03.007"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00105-19"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105925"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02409-16"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.11.008"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02307-18"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02309-18"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.8.4178-4182.2005"},{"key":"e_1_3_3_20_2","unstructured":"Louie A Robbins N Kurhanewicz S Fikes S Liu W Baluya D Brown D Shapiro S Pypstra R Drusano G. 2015. Pharmacodynamic evaluation of AAI101 a novel extended-spectrum beta-lactamase inhibitor (BLI) in combination with cefepime in hollow fiber models of ESBL enterobacterial infection. Abstr 55th Intersci Conf Antimicrob Agents Chemother San Diego CA 17\u201321 September 2015."},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00180-20"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2210"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.09.004"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.09.009"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1643-1646.2003"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2006.09.004"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01580-16"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00267-17"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00727-15"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02513-12"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01052-17"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.00078-15"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00001-19"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2018.04.004"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00033-15"},{"key":"e_1_3_3_36_2","unstructured":"Warn P Odedra R Gould J Knechtle P Shapiro S. 2018. Activity of a novel extended-spectrum \u03b2-lactamase inhibitor AAI101 combined with cefepime against \u03b2-lactamase-producing Enterobacteriaceae in a neutropenic murine pneumonia model. Abstr 28th ECCMID Madrid Spain 21\u201324 April 2018."},{"key":"e_1_3_3_37_2","volume-title":"Identifier NCT03687255: safety and efficacy study of cefepime-AAI101 in the treatment of complicated urinary tract infections","author":"ClinicalTrials.gov","year":"2018","unstructured":"ClinicalTrials.gov. 2018. Identifier NCT03687255: safety and efficacy study of cefepime-AAI101 in the treatment of complicated urinary tract infections. National Library of Medicine, Bethesda, MD."},{"key":"e_1_3_3_38_2","volume-title":"Abstr 30th Eur Cong Clin Microbiol Infect Dis","author":"Kaye KS","year":"2020","unstructured":"Kaye KS, Belley A, Lahlou O, Barth P, Motta P, Kashyap S, Knechtle P, Velicitat P. 2020. Outcomes of the novel \u03b2-lactam\/\u03b2-lactamase inhibitor combination of cefepime-enmetazobactam versus piperacillin-tazobactam in adult patients with complicated urinary tract infections\u2013the ALLIUM Phase 3 Trial. Abstr 30th Eur Cong Clin Microbiol Infect Dis, Paris, France."},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00607-19"},{"key":"e_1_3_3_40_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. M07-A10","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2015","unstructured":"Clinical and Laboratory Standards Institute (CLSI). 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. M07-A10. CLSI, Wayne, PA."},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05186-14"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22981"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbw122"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.00043-12"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz268"},{"key":"e_1_3_3_46_2","volume-title":"R: a language and environment for statistical computing","author":"R Development Core Team","year":"2008","unstructured":"R Development Core Team. 2008. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria."},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.11.2439"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00078-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00078-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:44:58Z","timestamp":1645461898000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00078-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,21]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,5,21]]}},"alternative-id":["10.1128\/AAC.00078-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.00078-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,21]]},"assertion":[{"value":"2020-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00078-20"}}